股票 
板块 
用户 
资讯 近日，美迪西上市七周年、中国药科大学建校90周年之际，美迪西与中国药科大学生命科学与技术学院正式签署产学研合作协议。双方将围绕新型偶联药物领域开展长期深度合作，打通从基础研究、技术攻关到产业应用的创新链条，推动产教融合高质量发展。
中国药科大学生命科学与技术学院院长、生物药物学院院长胡庆华，科学技术研究院副院长(正处级）张甜，生命科学与技术学院党委副书记姜玉涛，生物药物学院副院长尹骏，生命科学与技术学院生物技术与海洋药学系教授徐寒梅，生物药物学院蛋白与多肽药物系教授郭薇；美迪西创始人、董事长&CEO陈春麟，董事、副总经理、投融资发展部副总裁陈国铠，人力资源部副总裁陈华山，市场部总监陈思宇等出席签约仪式。
中国药科大学×美迪西
校企联动聚势能，产教融合激活创新内核
中国药科大学是中国第一所由国家创办的高等药学学府，其生命科学与技术学院深耕生物医药基础研究与高端专业人才培育多年，学科底蕴深厚、科研实力雄厚，是我国生物医药创新人才与源头技术的重要策源地。
美迪西作为国际一站式生物医药临床前研发服务CRO，服务覆盖药物发现、药学研究、临床前研究全过程，搭建了成熟完善的ADC、AOC、PDC等新型偶联药物技术平台，拥有丰富的项目落地、技术转化与产业化实操经验。
此次校企强强联手，实现了高校源头创新、人才储备与企业技术落地、产业赋能的双向互补、优势叠加，成功构建起“教育培育—科研创新—产业落地”三位一体的协同发展新生态。
五维协同发力
打造全链条创新研发闭环体系
为把战略协议转化为具体行动，双方聚焦人才、平台、科研、学术、转化五大维度，形成从源头创新到产业应用的闭环。具体合作内容如下：
人才共育：推动师资互聘与双向交流。美迪西开放实习实训平台与就业通道，设立企业奖学金、助学金、创新创业扶持资金，定向输送创新药领域高素质研发人才。
平台共建：共建“中国药科大学-美迪西新型偶联药物关键技术攻关联合实验室”，共享仪器设备与检测资源，开展AOC与ADC药物新型Payload-Linker协同设计、偶联关键技术攻关及工艺优化等应用基础研究。
科研协同：联合申报国家、省、市各级科技计划、自然科学基金、产业专项等科研项目；开展专项技术研究、样品检测、数据分析、技术论证等，并依托美迪西产业平台推进中试、工艺验证与产业化落地研究。
学术交融：联合举办学术论坛、技术研讨会、行业沙龙、学科竞赛等活动，支持人员互访、学术交流、进修深造、联合发表学术论文、申报科研奖励。
成果转化：中国药科大学为美迪西提供技术咨询、技术研发与难题攻关；校方优质创新成果依托美迪西成熟产业化平台，快速完成中试放大与商业化落地，高效将源头创新转化为产业硬核竞争力。
陈春麟
美迪西创始人、董事长&CEO
新型偶联药物是全球创新药核心赛道，亟需核心技术与高端人才。此次与中国药科大学深度合作，是美迪西面向国家生物医药战略需求、布局前沿技术的重要实践。美迪西将与中国药大科研育人体系深度耦合，助力破解创新药从基础研究到产业应用的转化难题，助力我国生物医药产业自立自强，迈向更高质量的国际化发展。
胡庆华
中国药科大学生命科学与技术学院院长、生物药物学院院长
美迪西深耕生物医药二十余年，在新型偶联药物领域积淀深厚，平台与转化经验和我院学科高度契合。本次合作是推进有组织科研、校企协同育人的重要探索。学院将依托美迪西打通基础研究到产业应用、课堂到实践的链路，培育产业创新骨干，加速科研成果转化，助力学子在实战中成长，为兴药强国、健康中国建设赋能。
关于中国药科大学
中国药科大学坐落于古都南京，始建于1936年，是我国历史上第一所由国家创办的药学高等学府。学校为教育部直属、国家“211工程”和“985工程优势学科创新平台”建设高校，2017年成为国家“双一流”建设高校，是一所以药学为特色的多科性、研究型大学，其中以药学、中药学学科为龙头的药学学科群建设始终保持国内领先水平，素有“中国生物医药人才摇篮”的美誉。2000年以来，实现本科和研究生教育国家级教学成果奖全覆盖，已4次获得我国教育领域政府类最高奖励——国家级教学成果奖（四年一届）一等奖。毕业生就业率长期位居教育部直属高校及江苏省高校前列。
关于美迪西
美迪西（股票代码：688202.SH）成立于 2004 年，专注于为全球制药企业、研究机构及科研工作者提供全方位的临床前新药研发服务。公司构建了覆盖药物发现、药学研究至临床前研究的一站式综合研发平台，并在 ADC/AOC、小核酸、多 (环) 肽、TPD、RIPTAC等前沿领域搭建了服务平台。公司建立了符合国际规范的质量体系，已获得中国 NMPA、美国 FDA、 OECD 等 GLP 认证以及 AAALAC 国际认证。目前，公司在上海和Boston拥有约 9.2 万平方米研发实验室。至 2026 年 6 月末，公司已为全球超 2000 家客户提供药物研发服务，参与研发完成的新药项目已有近 700 件 IND临床批件。美迪西将继续携手国内外合作伙伴共同推动药物创新，为人类健康贡献力量。欢迎访问公司官网 www.medicilon.com.cn 了解更多详情。
Medicilon and China Pharmaceutical University Forge Industry-University Research Collaboration on Novel Conjugate Therapeutics to Empower New Drug Innovation
November 5 marks the 7th anniversary of Medicilon’s listing and the 90th anniversary of the founding of China Pharmaceutical University (CPU). Recently, Medicilon and the School of Life Science and Technology of CPU officially signed an industry-university research cooperation agreement. The two parties will carry out in depth collaboration in novel conjugate therapeutics, bridging the innovation chain from basic research and technical breakthroughs to industrial application and advancing high-quality industry-education integration.
The signing ceremony was attended by Qinghua Hu, Dean of the School of Life Science and Technology and Dean of the School of Biopharmaceuticals, China Pharmaceutical University; Tian Zhang, Deputy Director (at the division-chief level) of the Office of Scientific Research; Yutao Jiang, Deputy Party Secretary of the School of Life Science and Technology; Jun Yin, Associate Dean of the School of Biopharmaceuticals; Hanmei Xu, Professor in the Department of Biotechnology and Marine Pharmacy, School of Life Science and Technology; Wei Guo, Professor in the Department of Protein and Peptide Drugs, School of Biopharmaceuticals; Chairman and CEO Chunlin Chen; Director, Deputy General Manager and Vice President of the Investment and Financing Development Department Guokai Chen; Vice President of Human Resources Huashan Chen; and Marketing Director Siyu Chen.
Industry-University Partnership Drives New Drug Innovation
CPU is China’s first state founded higher pharmaceutical institution. Its School of Life Science and Technology has long focused on basic biomedical research and cultivation of high-level specialized talents. Boasting solid disciplinary foundations and strong research capacity, it serves as a key hub for nurturing biomedical innovators and generating cutting-edge foundational technologies in China.
Medicilon is an international CRO providing one-stop preclinical R&D services for pharmaceuticals. Its service scope spans drug discovery, pharmaceutical development and preclinical studies. Medicilon has established well-developed technology platforms for ADCs, AOCs, PDCs and other novel conjugate therapeutics, with extensive hands-on experience in project delivery, technology translation and industrialization.
This partnership combines the university’s strengths in foundational innovation and talent pipeline development with Medicilon’s capabilities in technical implementation and industrial translation. It creates a mutually complementary ecosystem integrating talent training, scientific research and industrial translation.
Five Focus Areas to Build a Closed-Loop Full-Channel R&D System
The agreement sets out cooperation in five areas:
Joint Talent Development: Faculty exchanges and joint appointments, with Medicilon opening its internship, training and recruitment channels to CPU students. Medicilon will also fund corporate scholarships, bursaries and startup support, creating a route for graduates into innovative drug R&D.
Joint Platform Development: The two parties will establish the CPU–Medicilon Joint Laboratory for Key Technologies in Novel Conjugate Drugs, sharing instruments and analytical resources. Initial work will focus on the co-design of novel payload-linker systems for AOCs and ADCs, conjugation technologies and process optimization.
Collaborative Research: Joint applications for national, provincial and municipal science and technology programs, natural science foundation grants and industry funding. The partners will also carry out targeted technical studies, sample testing, data analysis and technical validation, with Medicilon's platforms supporting pilot-scale production, process validation and industrialization.
Academic Exchange: Joint forums, technical seminars, industry salons and student competitions, along with staff visits, academic exchanges, further study, coauthored publications and joint applications for research awards.
Technology Transfer: CPU will provide technical consulting, contract research and problem-solving support to Medicilon. In the other direction, CPU's research outputs will use Medicilon's platforms to move through pilot scale-up and into commercialization.
Chunlin Chen
Chairman and CEO of Medicilon
Novel conjugate drugs are one of the most competitive areas in global drug innovation, and they depend on both core technologies and specialized talent. This collaboration with CPU is part of Medicilon's effort to align our work with national priorities in biomedicine and to build capability in frontier technologies. Working directly with CPU's research and training programs should shorten the path from basic research to industrial application.
Qinghua Hu
Dean of the School of Life Science and Technology and Dean of the School of Biopharmaceuticals, China Pharmaceutical University
Medicilon has worked in biomedicine for more than two decades and has deep experience in novel conjugate drugs; its platforms and development track record fit closely with our school's research strengths. This partnership is a practical step in organized research and in training students alongside industry. It gives our faculty and students a route from the laboratory to application, and helps move research results into use.
About Medicilon
Founded in 2004, Medicilon (Stock Code: 688202.SH) is dedicated to delivering comprehensive preclinical drug R&D services to pharmaceutical enterprises, research institutions, and scientific investigators worldwide. The company has established a one-stop integrated R&D platform encompassing drug discovery, pharmaceutical research, and preclinical research, and has developed service platforms in cutting-edge fields including ADC/AOC, RNAi, peptides (including macrocyclic peptides), TPD, and RIPTAC. The company has instituted a quality system compliant with international standards and has secured GLP certifications from China's NMPA, the U.S. FDA, and the EU's OECD, along with AAALAC International accreditation. At present, the company operates approximately 92,000 square meters of R&D laboratory space across Shanghai and Boston. As of the end of June 2026, the company has provided drug R&D services to over 2,000 clients globally and has supported nearly 700 IND approvals. For more information, visit www.medicilon.com.
评论 (0)